Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 2

Status

Unknown 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Solid Tumor 2

Interventions

fludarabine 9Cyclophosphamide 9pembrolizumab 5Oncolytic Virotherapy 4Nivolumab 4Cholestanetriol 26-Monooxygenase 3atezolizumab 2alpha-Synuclein 2Trastuzumab 2Influenza Vaccines 2Blood Specimen Collection 2Ascorbic Acid 2tinostamustine 1sugemalimab 1spartalizumab 1ruxolitinib 1reolysin 1pexidartinib 1methyl prednisolonate 1irinotecan sucrosofate 1fiu protein, E coli 1camrelizumab 1avelumab 1apatinib 1VTX-2337 1Temozolomide 1TAK-981 1Sorafenib 1Radiation 1RXDX-106 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × INDUSTRY × alpha-Synuclein × Clear all
NCT03815084 2019-01-30

A Study of PD1 Combined With DC-NK Cell in the Treatment of Solid Tumors

Allife Medical Science and Technology Co., Ltd.

Phase EARLY_PHASE1 Unknown
100 enrolled
Other solid neoplasm

Solid Tumor

NCT03815630 2019-01-30

DC-CIK

Allife Medical Science and Technology Co., Ltd.

Phase EARLY_PHASE1 Unknown
100 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡